



vTv Therapeutics to Present a Poster at the American Diabetes Association's 78th Scientific Sessions

06/22/18

HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 22, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease, diabetes and other therapeutic areas, today announced that Company management will present a poster featuring vTv Therapeutics' liver-selective Glucokinase Activator at the American Diabetes Association's 78th Scientific Sessions held in Orlando, Fla., June 22–26, 2018.

Details of the presentations are listed below:

Late-Breaking Poster Title: "Simplici-T1 First Clinical Trial to Test Activation of Glucokinase as an Adjunctive Treatment for Type 1 Diabetes"

Poster Number: 126-LB

Category: 12-E Clinical Therapeutics/New Technology–Oral Agents

Date and Time: Monday, June 25, 2018, 12-1 pm ET

"As the first company to evaluate a Glucokinase Activator in people with type 1 diabetes, we are very excited to be sharing this clinical data at the American Diabetes Association's 78th Scientific Sessions," said Carmen Valcarce, Ph.D., executive vice president, chief scientific officer, vTv Therapeutics. "TTP399 was well tolerated in this small, open label, study in patients with type 1 diabetes and showed trends towards improving glycemic control while reducing insulin dose. Following these encouraging data, we are now evaluating TTP399 in a 12-week randomized, placebo-controlled, phase 2 study in type 1 diabetes to evaluate safety and efficacy".

About Simplici-T1

Simplici-T1 is a multi-center, randomized, double-blind, adaptive study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in adult patients with type 1 diabetes (T1D). This study is being conducted in two phases: Phase 1 evaluated the safety of ascending TTP399 dosage regimens in five patients each over one week of daily dosing; Phase 2 will evaluate the safety and efficacy of a TTP399 dosing regimen over twelve weeks of daily dosing. This study is being conducted with support from JDRF, the leading global organization funding T1D research.

About Type 1 Diabetes

Type 1 diabetes is an autoimmune disease in which a person's pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. Its onset has nothing to do with diet or lifestyle. There is nothing you can do to prevent T1D, and—at present—nothing you can do to cure it.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and diabetes as well as treatment of inflammatory disorders.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading "Risk Factors" in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause

our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180622005231/en/>

Source: vTv Therapeutics Inc.

vTv Therapeutics Inc.

Investors:

Mike Biega, 617-221-9660

IR@vtvtherapeutics.com

or

Media:

Josh Vlasto, 212-572-5969

PR@vtvtherapeutics.com